Plozasiran Lowers Cholesterol and Triglyceride Levels in Mixed Hyperlipidemia Patients, Study Finds

A recent study indicates that Plozasiran can lower both cholesterol and triglyceride levels in patients. The research focused on individuals diagnosed with mixed hyperlipidemia and related conditions that elevate cardiovascular risk. The findings suggest that Plozasiran influences key lipid markers. Specifically, the study observed reductions in both cholesterol and triglyceride levels within the patient cohort. Researchers conducted the investigation on individuals who had mixed hyperlipidemia and other conditions associated with increased cardiovascular risk. The study suggests a potential avenue for managing these complex lipid disorders.

Newsflash | Powered by GeneOnline AI
Date: May 9, 2025

Author

Mark Chiang